Alvaro Martinez Camarena is a Lecturer at the Department of Physical Chemistry, School of Chemistry, University of Valencia. His academic profile is centered on the development of azamacrocyclic ligand complexes as antioxidant enzyme mimetics, reflecting a focus on bioinorganic and supramolecular chemistry. PhD in Physical Chemistry (2019), University of Valencia Research interests include molecular design of macrocyclic compounds, antioxidant activity modeling, and coordination chemistry applications in biological systems. His work intersects physical chemistry principles with chemical biology and catalysis. No scientific awards are mentioned in the provided text. No student advising information or publications are listed in the available data.
Professor Kristian Strømgaard is a distinguished academic at the University of Copenhagen, where he holds a Professorship in Chemical Biology within the Department of Drug Design and Pharmacology at the Faculty of Pharmaceutical Sciences. His research focuses on the intersection of chemistry and biology, particularly in developing novel chemical tools and therapeutic approaches. With over two decades of academic experience, he has established himself as a leading figure in medicinal chemistry and chemical biology research in Denmark and internationally. Professor Strømgaard's educational background includes: 1996: M.Sc. Chemical Research, University College London, UK 1996: M.Sc. Pharmacy, Royal Danish School of Pharmacy, Copenhagen 1999: Ph.D. Medicinal Chemistry, Royal Danish School of Pharmacy, Copenhagen Professor Strømgaard's research interests center on chemical biology with a particular focus on peptide chemistry, neuropharmacology, and drug design. His work bridges the gap between synthetic chemistry and biological applications, developing novel chemical tools to study biological processes and create potential therapeutics. He has made significant contributions to understanding membrane permeability of cyclic peptides, developing macrocyclic inhibitors, and creating synthetic probes for neuroscience applications. His research integrates medicinal chemistry, pharmacology, and molecular biology to address complex biological questions with chemical solutions. Professor Strømgaard's recent publications demonstrate a strong focus on peptide-based drug development, neuropharmacology, and chemical tool development. His research spans from fundamental chemical biology investigations to translational applications, with particular emphasis on cyclic peptides, membrane permeability, and neuroreceptor modulation. The interdisciplinary nature of his work is evident in collaborations across chemistry, neuroscience, and pharmacology domains. Among his notable scientific achievements are: 1997: The British Chevening Award 2000: The Krka Award 2004: The Hede Nielsen Award Professor Strømgaard has been actively involved in academic mentoring and research funding. He has supervised 8 postdocs, 8 PhD students, and 22 MSc students throughout his career. His research group, the Chemical Biology group, currently comprises approximately 20 members and receives funding from multiple prestigious sources including H. Lundbeck A/S, the University of Copenhagen's Programs of Excellence, The Danish Medical Research Council, The Strategic Research Council, The Alfred Benzon Foundation, The Lundbeck Foundation, and The Carlsberg Foundation. As head of the Chemical Biology group, Professor Strømgaard leads a dynamic research team focused on innovative approaches in chemical biology and drug discovery. He also serves as the academic coordinator for the "Brain, Mind, & Medicines" trans-faculty network at the University of Copenhagen, fostering interdisciplinary collaboration across neuroscience, pharmacology, and medicine.
Albert A. Bowers is an Adjunct Associate Professor in the Department of Chemistry at the University of North Carolina at Chapel Hill. He is affiliated with the Division of Chemical Biology and Medicinal Chemistry (CBMC), the Center for Integrative Chemical Biology and Drug Discovery, and the Lineberger Comprehensive Cancer Center. His research integrates medicinal chemistry, biochemistry, and computational methods to develop peptide-based therapeutics using mRNA display technology. Education: BA, The University of Chicago, 2001 PhD, University of Illinois at Chicago, 2007 NIH Postdoctoral Fellow, Harvard Medical School, 2008-2011 Research Focus: Dr. Bowers' lab specializes in creating macrocyclic peptide libraries via mRNA display and biocatalysis. Key themes include advancing peptide macrocyclization techniques using enzymes like tyrosinase and microbial transglutaminase, and targeting challenging therapeutic areas such as protein-protein interactions and cancer antigens. Research combines biochemical library synthesis, bioinformatics, and structure-based design. Publications: Recent work emphasizes enzymatic methods for peptide cyclization and mRNA display optimization, reflecting a consistent focus on improving the pharmacological profiles of macrocyclic therapeutics against undruggable targets. Awards: Beckman Young Investigator Award (2014-2018) Boulder Peptide Society Young Investigator Award (2016) Collaborations & Labs: Leads the Bowers Lab focused on peptide macrocycle discovery. Collaborates with UNC researchers on targets including cancer antigens (MAGE-A4), checkpoint receptors (EGFR, B7-H3), GPCRs (Bryan Roth Lab), and ubiquitin pathways (Nick Brown Lab). Funded projects address high-value therapeutic targets lacking small-molecule solutions.
Scott Miller is the Sterling Professor of Chemistry and Department Chair at Yale University's Department of Chemistry within the Faculty of Arts and Sciences. He is also affiliated with the Yale Cancer Center as a member of the Developmental Therapeutics Program, demonstrating the translational nature of his research. Professor Miller's research focuses on the creation of new catalysts for complex molecule synthesis and derivatization, with particular emphasis on peptide-based catalysts for enantioselective reactions. His lab explores the application of asymmetric catalysis principles to regioselectivity, site-selectivity, and chemoselectivity, especially in natural product diversification. The Miller Lab targets molecular functionality ubiquitous in complex natural products to use these materials as scaffolds for new bioactive entity synthesis. Recent publications reveal significant advances in areas including atropisomerism, enantioselective hydrodifluoroalkylation of alkenes, catalyst-controlled regiodivergent oxidation, and site-selective protein editing. His work bridges fundamental chemical principles with potential biomedical applications through his cancer center affiliation. Professor Miller maintains an active research program with numerous high-impact publications in leading chemistry journals including Nature Chemistry, Journal of the American Chemical Society, and Nature Chemical Biology. His research demonstrates consistent innovation in catalytic methodology development and application to complex molecular systems. The Miller Lab employs combinatorial methods for catalyst screening and optimization, drawing mechanistic analogies to enzymes while developing novel peptide-based catalytic platforms. This approach has enabled significant advances in selective synthesis of complex molecules with potential applications in medicinal chemistry and drug discovery.
Laura Cleghorn serves as a Reader (Teaching and Research) in the Drug Discovery Unit within the School of Life Sciences at the University of Dundee. She is an active member of the Wellcome Centre for Anti-Infectives Research, contributing to the university's global reputation in infectious disease research. Dr. Cleghorn's research focuses on the discovery and development of novel therapeutics for tuberculosis and parasitic diseases, particularly African trypanosomiasis. Her work spans multiple approaches including targeting MmpL3, lysyl tRNA synthetase, and Pks13 for tuberculosis treatment, and developing N-myristoyltransferase inhibitors for trypanosomiasis. Her fingerprint analysis shows strong expertise in Mycobacterium tuberculosis (100%), Trypanosoma brucei (69%), and drug discovery (57%). Her publication record demonstrates consistent productivity from 2009 through 2025, with recent work focusing on tuberculosis drug targets. She has published in high-impact journals including ACS Infectious Diseases and Journal of Medicinal Chemistry, often serving as corresponding author on key papers. Brian Cox Prize for Excellence in Public Engagement with Research (2024) Science For All Badge (2023) Dr. Cleghorn is actively involved in grant-funded research and collaborates extensively within the Drug Discovery Unit and with international partners. Her work contributes to UN Sustainable Development Goals related to good health and well-being through the development of new treatments for infectious diseases that disproportionately affect vulnerable populations. She leads multiple research projects within the Drug Discovery Unit and is particularly noted for her contributions to public engagement, making complex drug discovery concepts accessible through exhibitions, talks, and interactive educational materials.
Mihaela Florea is a Scientific Researcher I at the National Institute of Material Physics in Magurele, Romania, and a Senior Researcher at the Catalysis and Catalytic Processes Research Center, Faculty of Chemistry, University of Bucharest. With over 20 years of research experience in heterogeneous catalysis and materials science, her work bridges fundamental science with practical applications in energy conversion, sustainable chemistry, and environmental remediation. Education: PhD in Chemistry, Université Catholique de Louvain (1999-2003), Thesis: 'Relationship between structure and activity of vanadium aluminium oxynitrides in propane ammoxidation' - awarded 'La plus grande distinction' Master of Science in Catalysis, University of Bucharest (1997-1999), Thesis: 'Ru-MCM-41 catalysts for stereocontrolled hydrogenation of prostaglandin intermediates' Master of Science in Project Management, Academy of Economics Studies, Bucharest (2005-2007) Dr. Florea's research focuses on catalytic applications of novel 2D materials, particularly MAX phases and MXenes, for energy-related processes. Her work encompasses design of electrocatalysts for OER, HOR, and ORR reactions, hydrogen production through water splitting, and catalytic selective oxidation of methane and biomass derivatives. She has pioneered approaches for converting polyethylene terephthalate to valuable chemicals using acid-modified MXenes and developed catalysts for sustainable production of platform chemicals from renewable resources. Analysis of her recent publications reveals a strong interdisciplinary focus spanning materials chemistry, catalysis, and energy science. Her work consistently demonstrates innovation in synthesizing and characterizing advanced catalytic materials, with particular emphasis on structure-property relationships. The research shows increasing sophistication in utilizing 2D materials for energy applications, with growing attention to environmental sustainability and circular economy principles. Scientific Recognition: Romanian Academy award 'I.G. Murgulescu' (2020) With 12 years of teaching experience at the University of Bucharest, Dr. Florea has supervised numerous bachelor's and master's students in catalysis and analytical chemistry. Her research is supported by significant projects including ERC-LIKE funding for '2D metallic carbide as active and selective catalysts for direct oxidation of CH4' and M-ERANET funding for 'Holistic design of fuel cell electrocatalysts.' She holds three patents related to catalytic processes and has contributed to a book chapter on biomass conversion. Dr. Florea leads research in the Laboratory of Catalytic Materials and Catalysis, employing advanced characterization techniques including XPS, BET, Raman spectroscopy, XRD, FTIR, and electron microscopy to investigate material properties and catalytic mechanisms. Her work environment fosters innovation in sustainable materials design with practical applications in energy and environmental technology.
Dr. Seah Ling Kuan serves as Group Leader of the Protein Therapeutics group at the Max Planck Institute for Polymer Research (MPI-P) and has been Head of the Mass Spectrometry Core Facility since October 2022. Her work bridges chemical design and cancer therapeutics with a focus on tumor microenvironment (TME) interventions. Her academic foundation includes: B.Sc. (Hons) from National University of Singapore (2003) Ph.D. from National University of Singapore (2009) Research centers on protein-based nanomedicine targeting the TME as a dynamic ecosystem. Her group develops catalytic biopolymers for sustained therapeutic effects and utilizes 3D cell models to study biotherapeutic interactions. Collaborative mass spectrometry imaging enables label-free metabolite tracking and TME mapping, emphasizing strategies beyond direct cancer cell destruction to prevent metastasis. Recent publications (2021-2025) demonstrate expertise in stimuli-responsive drug delivery systems and precision bioconjugation , spanning chemistry, nanomedicine, and immunology. Key trends include tumor-targeted photosensitizers, sequence-controlled release mechanisms, and glycogen-mimetic nanocarriers for immune modulation, reflecting interdisciplinary innovation in cancer therapy. Key recognition: Alexander von Humboldt Fellowship (2011) Dr. Kuan directs both the Protein Therapeutics group and Mass Spectrometry Core Facility, leveraging her role as Europe Coordinator for the Singapore National Institute of Chemistry Overseas Members Network. Previous positions include group leader at the Institute of Organic Chemistry III (2013-2016) and scientific roles at Singapore's Health Authority Sciences. The Protein Therapeutics group pioneers catalytic biotherapeutics for TME modulation, while the Mass Spectrometry Core Facility advances imaging techniques for metabolite biodistribution studies in complex biological systems.
Katsuhiko Ono serves as Associate Professor in the Department of Life and Applied Chemistry at Nagoya Institute of Technology's Faculty of Engineering. His research bridges organic synthesis and materials engineering with emphasis on functional molecular design for electronic applications. Current investigations focus on boron-containing $$\pi$$-conjugated systems and supramolecular architectures. His academic foundation includes: Doctor of Science from The Graduate University for Advanced Studies (1995) Master of Science from Shinshu University (1992) Bachelor of Science from Shinshu University (1990) Professor Ono's research program centers on structural organic chemistry and physical organic chemistry, particularly the development of boron-based chromophores for organic photovoltaics. His work explores regioselective functionalization of diketones via $$\text{BF}_2$$ complexes, $$\beta$$-ketoiminate dye synthesis, and $$\pi$$-extended semiconductor design. This integrates nanotechnology, solid-state chemistry, and bioorganic principles to create materials with tailored optoelectronic properties. Analysis of his 2015-2025 publications reveals consistent innovation in boron chemistry for renewable energy applications. Key trends include developing air-stable donor-$$\pi$$-acceptor dyes, mechanochromic $$\text{BF}_2$$ complexes, and n-type semiconductors using dioxaborin scaffolds. His approach combines synthetic precision with device-oriented characterization to advance organic electronics. His recognition includes: Nagoya Institute of Technology Staff Commendation (Excellent Award) (2009) Professor Ono has secured five consecutive Japanese Ministry of Education Grants-in-Aid for Scientific Research (C) from 2007-2022, totaling over 100 million yen for projects on non-fullerene acceptors, boron-based dyes, and molecular nanostructures. He actively mentors students through collaborative publications and serves on national committees including the Chemical Society of Japan's Tokai Branch Executive Committee. His laboratory maintains strong industry partnerships in photovoltaics and participates in the Central Japan Chemical Societies Federation, with recent media features on next-generation science leadership in Aichi Prefecture.
Ana Čikoš is a Senior Research Associate at the NMR Centre of Ruđer Bošković Institute (RBI) in Zagreb, Croatia. Her research specializes in NMR spectroscopy applications for pharmaceutical and analytical chemistry, including drug discovery, structural biology, and natural products analysis. She mentors graduate students and collaborates extensively on interdisciplinary projects. Education PhD in Analytical Chemistry (2011), University of Zagreb: Thesis on NMR studies of macrolide-ribosome interactions. B.Sc. in Chemistry (2003), University of Zagreb: Thesis on NMR conformational analysis of macrocyclic drugs. Her research integrates NMR spectroscopy with drug design, focusing on macrocycles, protein-ligand interactions, and degradation pathways. She develops methods for structural elucidation of natural products and pharmaceutical impurities, contributing to drug development pipelines. Publications emphasize NMR methodology, macrocyclic therapeutics, and cyclodextrin complexes, with consistent output in high-impact journals since 2007. Recent work explores inflammation targets and asymmetric membrane characterization. Awards "You made the difference!" Award (Fidelta, 2018) GSK Silver Award for NMR lab modernization (2010) GSK Exceptional Science Award for ribosome studies (2009) GSK Bronze Award for macrolide PK research (2008) GSK Silver Award for Open Access NMR implementation (2007) She advises graduate researchers on NMR-based projects and has supervised diploma theses on cyclodextrin complexes and macrocyclic conformation. She leads collaborative initiatives like the Remote NMR infrastructure project.
Dr. Mladena Glavaš is a Researcher at the NMR Centre of the Ruđer Bošković Institute in Zagreb, Croatia, specializing in organic synthesis and biochemical applications. Her work integrates advanced spectroscopic techniques with molecular design to develop novel compounds for biological and medical research. Her research focuses on Organic Chemistry with emphasis on Peptide Chemistry and Fluorescent Dye Development . Key areas include synthesizing modified amino acids for peptide engineering, designing BODIPY-based fluorescent sensors for cellular imaging, and creating photochemically reactive compounds for DNA interaction studies. Her work bridges synthetic organic chemistry with biochemical applications, particularly in developing tools for intracellular visualization and molecular recognition. Analysis of her 2017-2025 publications reveals consistent innovation in fluorescent probe design—especially BODIPY derivatives for pH sensing and organelle staining—and peptide modification techniques. Her research demonstrates strong interdisciplinary connections between synthetic chemistry, photochemistry, and biomedical applications, with increasing focus on practical tools for cellular imaging and molecular diagnostics. Dr. Glavaš serves as academic supervisor, having directed Antonija Karakaš's 2023 master's thesis on oligopeptide photophysics at the Faculty of Chemical Engineering and Technology in Zagreb. Her collaborative work spans international institutions including Polish and Israeli research groups, reflecting strong cross-border scientific engagement.
Ngong Kodiah Beyeh serves as an Associate Professor in the Department of Chemistry within Oakland University's College of Arts and Sciences. Based in the Mathematics and Science Center (Room 205), Dr. Beyeh leads an active research program at the intersection of supramolecular chemistry, materials science, and biotechnology. Research interests focus on functional materials via receptor chemistry , halogen-bonded architectures , and molecular recognition systems . Key projects include designing macrocycles for biomedical applications against antibiotic-resistant pathogens, developing asphaltene dispersants for petroleum processing, and engineering halogen-bonded polymeric materials. The research integrates synthetic chemistry with biophysical characterization across gas, solution, and solid phases. Recent publications reveal strong trends in supramolecular biomaterials (2021-2024), with significant work on halogen bonding (2015-2021) and foundational host-guest chemistry (2008-2018). The portfolio demonstrates consistent innovation in macrocycle design for applications spanning biotechnology, petroleum science, and advanced materials. Education includes a Ph.D. in Organic Chemistry (2008) and M.Sc. in NanoScience (2004) from the University of Jyväskylä, Finland, and a B.Sc. in Chemistry (2000) from the University of Buea, Cameroon. Postdoctoral training spans Finland (Academy of Finland Postdoc, 2012-2015), Germany (Free University of Berlin), and the USA (University of Texas at Austin). The Beyeh Lab maintains active research in supramolecular materials science, with current projects targeting Gram-negative pathogens, asphaltene dispersants, and halogen-bonded polymeric systems. The laboratory leverages multiple weak interactions to construct complex chemical systems with applications in biotechnology and industrial processes.
